PG4 Multivalent Vaccine

Phase 3

Pfizer

PG4 Multivalent Vaccine is one of 4 therapeutic programs targeting Pneumococcal Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pneumococcal DiseaseNot yet recruiting

Pneumococcal DiseasePhase 3

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Pneumococcal Disease

#DrugCompanyPhaseTrials

Pneumococcal Vaccine

GSK

Phase 3

1 2

PG4

Pfizer

Phase 3

4 3

20vpnc

Pfizer

Phase 3

2 4

PG4 Multivalent Vaccine

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Pneumococcal Disease

NCT07794748

Clinical

Trials by Indication[1]

Pneumococcal Disease1 trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

Not yet recruiting· Pfizer logo

Pfizer·Phase 3·NCT07794748·4,670 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PG4 Multivalent Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for PG4 Multivalent Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Pfizer

PG4 Multivalent Vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Pneumococcal Disease1 trial

References

Drug Info

Quick Facts

Related News